Form 483

InvaGen Pharmaceuticals, Inc. Form 483, 2015-03-13

FDA issued a Form 483 to InvaGen Pharmaceuticals, Inc. on 2015-03-13 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

InvaGen Pharmaceuticals, Inc. · Hauppauge, United States · Issued March 13, 2015

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Mar 2015
21 CFR 211.142

Written warehousing procedures established/followed

Cited by Alice S Tsao, Mindy M Chou

13 Mar 2015
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Alice S Tsao, Mindy M Chou

13 Mar 2015
21 CFR 211.67(b)

Written procedures fail to include

Cited by Alice S Tsao, Mindy M Chou

13 Mar 2015
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Alice S Tsao, Mindy M Chou

13 Mar 2015
21 CFR 314.80(c)(2)

Late submission of quarterly safety reports

Cited by Alice S Tsao, Mindy M Chou

Inspected site

IPInvaGen Pharmaceuticals, Inc.Hauppauge, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.142Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere